Loss of heterozygosity of TP53 is not correlated with clinicopathological variables in sporadic colorectal carcinomas

Anticancer Research

Volumn 19, Issue 2 A, 1999, Pages 1325-1329

  Gonzalez Aguilera J J ^a   Palicio Herrero, M ^a   Maillo, C ^b   Moreno Azcoita, M ^b   Fernandez Peralta A Ma ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Clinicopathological variables; Loss of heterozygosity; Sporadic colorectal carcinoma; TP53

Indexed keywords

MICROSATELLITE DNA; PROTEIN P53;

AGED; ARTICLE; CANCER STAGING; CHROMOSOME 17P; CLINICAL FEATURE; COLORECTAL CARCINOMA; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION;

EID: 2442726738     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Cho KR and Vogelstein B: Supressor gene alterations in the colorectal adenocarcinoma sequence. J Cell Biochem 16: 137-141, 1992.
2. Baker SJ, Preisinnger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, Hamilton S and Vogelstein B: p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50: 7717-7722, 1990.
3. Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-455, 1991.
4. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM and Bos JL: Genetic alterations during colorectal tumor-development. N Eng J Med 319: 525-532, 1988.
5. Campo E, de la Calle O, Miquel R, Palacín A, Romero M, Fabregat V, Vives J, Cardesa A and Yagüe J: Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Res 51: 4436-4442 1991.
6. Shi C-Y, Phang T-W, Ngoi S-S, Wee A, Li B, Lin Y, Lee H-P and Ong CN: Characterization of p53 gene mutations in colorectal carcinomas from Asian population. Anticancer Research 14: 2871-2816, 1994.
7. Legget B, Young J, Buttenshaw R, Thomas L, Young B. Chenevix-Trench G, Searle J and Ward M: Colorectal carcinomas show frequent allelic loss on the long arm of chromosome 17 with evidence for a specific target region. Br J Cancer 71: 1070-1073, 1995.
8. Cottu PH, Muzeau F, Estreicher A, Fléjou JF, Iggo R, Thomas G, and Hamelin R: Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. Oncogene 13: 2727-2730, 1996.
9. Proser J, Thompson AM, Cranston G and Evans HJ: Evidence that p53 behaves as a tumor suppressor gene in sporadic breast tumors. Oncogene 5: 1573-1579, 1990.
10. Varley JM, Brammar WJ, Lane DP, Swallow JE, Dolan C and Walker RA: Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 6: 413-421, 1991.
11. Voglino G, Castello S, Silengo L Stefanuto G, Friard O, Ferrara G and Fessia L: An intronic deletion in TP53 gene causes exon 6 skipping in breast cancer. Eur J. Cancer 33: 1479-1483, 1997.
12. Weston A, Willey JC, Modali R, Sugimura H, McDowell EM, Resau J. Light B, Haugen A, Mann DL, Trump BF and Harris CC: Differential DNA sequence deletions from chromosomes 3, 11, 13 and 17 in squamous-cell carcinoma, large-cell carcinoma, and adenocarcinoma of the human lung. Proc Natl Acad Sci USA 86: 5099-5103, 1989.
13. Tsai YC, Nichols PW, Hiti AL, Skinner DG and Jones PA: Allelic losses of chromosome 9, 11 and 17 in human bladder cancer. Cancer Res 50: 44-47, 1990.
14. Rhyu M-G, Park W-S, Jung Y-J, Choi S-W and Meltzer SJ: Allelic deletions of MCC/APC and p53 are frequent late events in human gastric carcinogenesis. Gastroenterology 106: 1584-1588, 1994.
15. James CD, Carlbom E, Nordenskjöld M, Collins VP and Cavenee WK: Mitotic recombination of chromosome 17 in astrocytomas. Proc Natl Acad Sci USA 86: 2858-2862, 1989.
16. Lin D, Shields MT, Ullrich SJ, Apella E and Mercer WE: Growth arrest induced by wild-type protein blocks cells prior to or near the restriction point in late phase. Proc Nat Acad Sci USA 89: 9210-9214, 1992.
17. Livigstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923-935, 1992.
18. Shaw P, Bovey R. Trady S, Sahli R, Sordat B and Costa J: Induction of apoptosis by wild type p53 in a human colon tumour-derived cell line. Proc Nat Acad Sci USA 89: 4495-4499, 1992.
19. Rodrigues NR, Rowan A, Smith MEF, Kerr IB, Bodmer WF, Gannon JV and Lane DP: p53 mutations in colorectal cancer. Proc Nat Acad Sci USA 87: 7555-7559, 1992
20. Finlay CA, Hinds PW, Tan TH. Eliyahu D, Oren M and Levine AJ: Activating mutations for transformation by p43 product that forms a hsp 70-p53 complex with an altered half-life. Mol Cel Biol 8: 531-539, 1988.
21. Scott N, Sagar P, Sreqart J, Blair GE, Dixon MF and Quirke P: p53 in colorectal cancer: clinico-pathological correlations and prognostic significance. Br J Cancer 63: 317-319, 1991.
22. Zeng ZS, Sarkis AS, Zhang ZF, Klimstra DS, Charytonowicz E, Guillén JG, Cordoncardo C and Cohen AM: p53 nuclear overcxpression: an independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 12: 2043-2050, 1994.
23. Bertorelle R, Esposito G, Belluco C, Bonaldi L, Del Mistro A, Nittri D, Lise M and Chieco-Bianchi L: p53 gene alterations and protein accumulation in colorectal cancer. J Clin Pathol 49: 85-90, 1996.
24. Jackson PA, Green MA, Pouli A, Hubbard R, Marks CG and Cook MG: Relation between stage, grade, proliferation and expression of p53 and CD44 in adenomas and carcinomas of the colorectum. J Clin Pathol 48: 1098-1101, 1995.
25. Lazaris AC, Theodoropoulos GE, Anastassopoulos P, Nakopoulos L, Panoussopoulos D and Papadimitrou K: Prognostic significance of p53 and c-erbB-2 inmunohistochemical evaluation in colorectal adenocarcinoma. Histol Histopathol 10: 661-668, 1995.
26. Mulder JWR, Baas IO, Polak MM, Goodman SN and Offerhaus GJA: Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 71: 1257-1126, 1995.
27. Rhine K, Goh HS, and Smith DR: Significance of chromosome 5q and 17p allelic deletion in colorectal adenocarcinomas. Int J Oncol 7: 631-635, 1995.
28. Takanishi DMJr, Angriman I, Yaremko ML, Montag A, Westbrook CA and Michelassi F: Chromosome 17p allelic loss in colorectal carcinoma. Arch Surg 130: 585-589, 1995.